AstraZeneca sets sights on $80B in revenue by 2030
BioPharma Drive: Drug Pricing
MAY 21, 2024
pharma expects to launch 20 new drugs by then, among them complex medicines for cancer as well as treatments for weight loss.
Public consultation of experts to join the Guideline Development Group (GDG) for Defeating Meningitis by 2030 Roadmap: Meningitis diagnosis, treatment and care guidelines
The Pharma Data
MAY 1, 2023
In response, WHO, together with global partners and experts, took the leadership in developing a global strategy that sets forth a vision and roadmap to defeat meningitis by 2030. In November 2020, this global roadmap on meningitis was approved by the Seventy-Third World Health Assembly (resolution WHA73.9).
Treatment 
40
40 
Cannabinoids Unleashed: Innovative Treatments in Medicine and Cosmetics
biobide
DECEMBER 1, 2023
Cannabis derivatives In 2022 the global legal cannabis market was valued at USD 22.1 This is forecasted to grow rapidly, with a growth rate of 25.5% A Key contributing factor to this significant growth prediction is the accelerating legalization of cannabis products and the growing acceptance of its use in the medical field and consumer goods.
Treatment 97
97 
World Health Assembly endorses bold new road map targets for 2030
The Pharma Data
NOVEMBER 12, 2020
Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030 sets out global targets and actions to align and re-focus the work of countries, partners and stakeholders during. 2030 road map targets. now have the consensus and the commitment of every country to work in.
Disease 52
52 
Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
The Pharma Data
MAY 31, 2022
The initiative is supported by a multidisciplinary Steering Committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world, with a mission to increase global adoption of biosimilar medicines by at least 30% in 30+ countries by 2030.
Biosimilars 52
52 
Development of Blood-Based Alzheimer’s Prognostic Propels Diadem to Finalist Status for Both the Gaetano Marzotto Company Prize and 2030 Social Impact Special Prize
The Pharma Data
NOVEMBER 15, 2020
16, 2020 /PRNewswire/ — Diadem srl , a company developing the first blood-based test for the prediction of early onset Alzheimer’s disease, today announced that it has been selected as a finalist for both the Gaetano Marzotto Company Prize and the Gaetano Marzotto 2030 Social Impact Special Prize. . MILAN , Nov.
Disease 40
40 
Possible adulticidal drugs for Onchocerca volvulus
Drug Target Review
SEPTEMBER 21, 2023
The findings supported the possibility put forward by Cotton et al (2016) concerning the chance of repurposing these drugs for adulticidal treatment. The available treatment for that is minor surgery -to remove the nodules. With accessible and effective treatments, this is feasible. doi: 10.1002/14651858.CD011146.pub2.
Drugs 105
105 
More ways, to save more lives, for less money: World Health Assembly adopts more Best Buys to tackle noncommunicable diseases
The Pharma Data
MAY 26, 2023
The new list also includes secondary prevention for rheumatic fever, acute and long-term management of asthma and chronic obstructive pulmonary disease as well as several cancer control interventions related to cervical, breast, colorectal, liver and childhood cancer, and the comprehensive treatment of cancer for those living with HIV.
Disease 52
52 
Identify and Validate Innovative Peptides for the Treatment of Obesity
The Pharma Data
MARCH 2, 2021
Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. ii It is projected that by 2030, close to half of the U.S. NASH and type 2 diabetes, as well as for a number of cancers.
Treatment 52
52 
Investment Trends in Pharmaceutical Research
DrugBank
AUGUST 9, 2024
However, searching for broader applicability and personalized approaches continues, as not all patients respond to these treatments. In 2021, an estimated 537 million adults were living with diabetes, a number projected to reach 643 million by 2030. billion by 2030. The market for cardiovascular drugs, valued at 155.6
Advances in personalised medicine, leave data processing behind
Drug Target Review
DECEMBER 4, 2023
What’s more, investment in this sector is predicted to rise by 70 percent by 2030. Tailoring medical care to a patient’s unique genetic makeup, alongside the close analysis of disease progression, leads to more effective treatments, reduced side effects and faster diagnoses.
Treatment 105
105 
reporting continued progress towards elimination as a public health problem
The Pharma Data
NOVEMBER 2, 2020
billion cumulative treatments to more than 923 million people since 2000. The treatments target the parasites in the blood of infected people and prevent the risk of transmission in the community. Setting sights on 2030. Despite setbacks due to COVID-19, WHO will accelerate work to achieve this target by 2030.
Packaging 52
52 
Shaping the Future: Eli Lilly's Role in the Weight Management Revolution
DrugBank
MARCH 15, 2024
The weight loss industry has emerged as a major hub for innovative research, groundbreaking treatments, and economic opportunity. billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. With sales soaring to $2.2 for this class of drugs.
ORZILOBEN
New Drug Approvals
JANUARY 31, 2024
The prevalence of non-alcoholic steatohepatitis (NASH), a form of NAFLD that is associated with hepatic inflammation and ballooning of hepatocytes, is expected to increase by 63% between 2015 and 2030 in the United States (Estes, Hepatology, 2018; 67(1): 123-133), where NASH is expected to become the leading cause of liver transplantation by 2020.
Treatment 52
52 
WHO, Ghana and Norway agree to accelerate actions to save lives in first International Strategic Dialogue on Noncommunicable Diseases and the Sustainable Development Goals
The Pharma Data
APRIL 12, 2022
per person per year from now until 2030. This investment would realize more than US$ 230 billion in economic and societal benefits and avert nearly 10 million heart attacks and strokes globally by 2030. NCDs are largely preventable and treatable, nearly 7 million lives could be saved for just US$ 0.84
How organoids can redefine pre-clinical research
Drug Target Review
SEPTEMBER 22, 2023
The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030. Nat Rev Bioeng [Internet]. 2023 Jan 19;1(1):32–45. 95: 729–38
InnoCare Announces Clearance by the US FDA of Phase II Clinical Trial Using orelabrutinib for the Treatment of Multiple Sclerosis
The Pharma Data
NOVEMBER 1, 2020
billion by 2030 2. BTK inhibitors have the potential to transform the treatment paradigm of autoimmune diseases including MS. According to Frost & Sullivan analysis, global market of MS drugs reached US$23.0 billion in 2018, and it is expected to be up to US$48.9
The Race for Ozempic Alternatives: Unlocking the Future of Weight Loss Medication
DrugBank
MARCH 7, 2024
adults using obesity medications by 2030, further underlining the growing significance of this sector. Inspired by its success, pharmaceutical companies are pursuing the development of drugs with similar therapeutic profiles, aiming to expand treatment options. Goldman Sachs analysts anticipate a significant rise in the number of U.S.
Power to the Patient with Patient Generated Health Data
FDA Law Blog: Biosimilars
JULY 10, 2024
Using PGHD can help patients manage their own health and can help sponsors develop endpoints for studying impacts of new treatments that matter to patients. As for the future of PGHD, many panelists were asked how they envision use of PGHD in 2030.
Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule
The Pharma Data
MAY 15, 2023
The Company successfully met its 2030 target to increase energy efficiency, exceeded its 2030 target to reduce total water withdrawal in areas projected to be in water stress and met its 2023 targets to train employees on compliance policies.
Government 40
40 
WHA73 endorses resolutions on meningitis control and epilepsy, roadmap on neglected tropical diseases
The Pharma Data
NOVEMBER 12, 2020
Committee A, which focuses on programme and budget matters, decided to recommend the adoption of the first-ever resolution on meningitis, which would approve a global roadmap to defeat meningitis by 2030 – a disease that kills 300,000 people annually and leaves one in five of those affected with devastating long-term consequences.
Disease 52
52 
Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
The Pharma Data
APRIL 7, 2021
Additionally, Sanofi is committed to helping 1,000 patients living with rare diseases who have no access to treatments and will donate 100,000 vials of medicine for their treatments each year. Leveraging R&D efforts to address crucial treatment gaps. Pushing to build more diverse and inclusive workforce.
Vaccine 52
52 
Roche awarded WHO prequalification for the HIV and HCV tests on the cobas 6800/8800 Systems
The Pharma Data
MARCH 11, 2021
Roche is committed to helping countries scale up HIV elimination programs and reach the WHO 2030 goals of 95% of people living with HIV knowing their HIV status; 95% of HIV-positive people on treatment; and 95% of people on treatment having suppressed viral loads. About the Global Access Program.
Disease 52
52 
Updates in the Ophthalmology Clinical Landscape
Vial
APRIL 18, 2024
Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding. from 2023 to 2030. billion in 2022, is also expected to grow with a CAGR of 7.80% from 2023 to 2030. Dr. Stephen McLeod, M.D.,
Lilly’s donanemab receives U.S. FDA’s Breakthrough Therapy designation for treatment of Alzheimer’s disease
The Pharma Data
JUNE 28, 2021
The current annual societal and economic cost of dementia is estimated at $1 trillion, an amount that is expected to double by 2030 unless we find a way to slow the disease 2. In the US alone, there was an increase of 8 million new caregivers from 2015 to 2020 3.
Therapies 40
40 
World Malaria Day 2021
The Pharma Data
APRIL 24, 2021
Over the past 20 years, together with our partners, we have delivered nearly 1 billion treatments, including over 430 million pediatric treatments to malaria-endemic countries. Novartis is advancing Research & Development of next-generation treatments to combat emerging drug resistance. 50-51) (PDF 6.3 Read the reports.
Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease
The Pharma Data
OCTOBER 9, 2021
Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). This Refinement Therapeutic Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous specific for the treatment of Alzheimer’s trouble with the prospect for at- home administration.”
Disease 52
52 
AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
The Pharma Data
MAY 26, 2023
With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. We will showcase significant steps toward that goal with overall survival data from ADAURA that reinforce Tagrisso as the backbone therapy in EGFR-mutated lung cancer.”
Therapies 40
40 
Addressing the Challenge of Antibiotic Resistance
DrugBank
NOVEMBER 4, 2024
trillion loss in GDP by 2030 shows the urgency of this crisis. Furthermore, AI-powered platforms are being employed to predict antibiotic susceptibility and resistance profiles, enabling the development of personalized treatment strategies that optimize antibiotic use and minimize the risk of resistance emergence.
Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research
Vial
MAY 20, 2024
In the field of clinical research , this pipeline can be broken down into several stages and processes specifically designed to rigorously validate the safety and efficacy of new drugs and treatments. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. What is a Pre-Clinical CRO?
First-ever global commitment to eliminate a cancer
The Pharma Data
NOVEMBER 16, 2020
WHO‘s Global Strategy to Accelerate the Elimination of Cervical Cancer, launched today, outlines three key steps: vaccination, screening and treatment. Meeting the following targets by 2030 will place all countries on the path toward elimination: 90% of girls fully vaccinated with the HPV vaccine by 15 years of age.
Vaccine 40
40 
Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease
The Pharma Data
OCTOBER 14, 2021
Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). “This Breakthrough Therapy Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous medicine for the treatment of Alzheimer’s disease with the potential for at-home administration.
Therapies 52
52 
WHO releases new estimates of the global burden of cervical cancer associated with HIV
The Pharma Data
NOVEMBER 16, 2020
rapid progression to cancer, lower chances of regression of pre-cancer lesions, higher rates of recurrence following treatment. . HPV vaccination, screening and treatment for cervical pre-cancer and cancer, which are critical to preventing and managing cervical cancer are yet to be fully scaled up, contributing. care by 2030.
Vaccine 52
52 
Iceland joins forces with WHO to support an integrated approach to brain health
The Pharma Data
DECEMBER 8, 2020
The brain health unit aims to achieve these goals by following a holistic person-centred approach that focusses on promotion, prevention, treatment, care and rehabilitation. foster increased investment and inter-agency collaboration globally as well as involvement of different specialties and sectors. 1] A73/A/CONF./2
Government 52
52 
Learning from history: Sanitation for prosperity
The Pharma Data
NOVEMBER 18, 2020
The disposal and treatment of human waste has been an integral part of human civilization for thousands of years. With only 10 years left until 2030, the rate at which access to sanitation is increasing will need to quadruple if the world is to achieve the Sustainable Development Goal (SDG) sanitation target. Source link.
Government 52
52 
BioArctic receives European patent for new antibodies targeting Alzheimer’s disease
The Pharma Data
JANUARY 26, 2021
27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan.
Disease 40
40 
Five Initiatives to Help Find the ‘Missing Millions’ of Undiagnosed People Living with Tuberculosis
The Pharma Data
MARCH 24, 2021
Successfully identifying these people, especially those living with multidrug-resistant TB (MDR-TB), remains one of the most significant obstacles in achieving the United Nations (UN) Sustainable Development Goal of ending TB by 2030. Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson.
Treatment 52
52 
ViiV?Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool
The Pharma Data
MAY 27, 2022
This builds on a long-standing partnership between ViiV Healthcare and MPP which has been highly successful in facilitating the manufacture and sale of low-cost versions of ViiV Healthcare medicines in countries most affected by HIV and least able to pay for treatment and care. Shionogi B.V. joined in October 2012.
Licensing 52
52 
Creating Great Medical Devices Digital Experiences for Baby Boomer Audiences
Perficient: Drug Development
AUGUST 8, 2023
By 2030, the last of the 73 million baby boomers will cross the threshold into Medicare eligibility. Many of us have a somewhat dated view of the 65-plus population, but these folks aren’t your grandma’s grandma. Boomers may have grown up in an analog-world, but they have been steadily riding the technology wave ever since.
Production 52
52 
The Forgotten Pandemic
Codon
OCTOBER 27, 2024
In 2014, the World Health Organization (WHO) proposed an initiative called the End TB Strategy , aimed at reducing cases by 80 percent, deaths by 90 percent, and diagnostic/treatment costs by 100 percent by 2030. In The Magic Mountain , patients receiving this treatment joined what they dubbed the “Half-Lung Club.”
Bayer delivers on medical innovation fueling transformation of pharma business
The Pharma Data
FEBRUARY 21, 2022
Our scientific leadership in the area of cardiovascular diseases advances our mission to provide better treatment options for patients in need.”. While pursuing research to find new treatment options for gynecological diseases with a high unmet medical need, the company is also working on addressing women’s health needs during menopause.
Women in STEM with Gilda Ascione
Drug Target Review
OCTOBER 1, 2024
The possibility of using new technologies to build new, more effective and less toxic therapies has opened new horizons for the treatment of cancer. Moreover, increasing treatment complexity will require more sophisticated scientific exchange. Oncology has come a long way in recent years.
Doctors 64
64 
Abbott launches new initiative to drive diversity in medical research and improve care among under-represented populations
The Pharma Data
NOVEMBER 6, 2021
This trouble builds on Abbott’s commitment of engaging populations who have historically been under- represented in medical exploration and will ameliorate health by adding access to innovative treatment options available within the trials process and adding perceptivity around how different groups respond to new curatives.
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
The Pharma Data
FEBRUARY 24, 2022
with more than 8 million cases expected by 2030. with preserved ejection fraction, a form of heart failure that has very limited treatment options.” . – FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. ” Affecting more than 6 million people in the U.S.,
FDA Approval 52
52 
Let's personalize your content